OKYO Pharma Ltd

OKYO Pharma operates with a negative equity position of £-5.55 million and a current ratio of 0.4, indicating significant liquidity constraints. The company's market capitalization stands at £84.49 million, with a market price of £1.61 per share. The enterprise value to EBITDA ratio is negative at -11.69, reflecting the company's current unprofitable status. The company has no long-term debt, but its operating cash flow is negative at £-1.81 million, and free cash flow is also negative at £-4.70 million.

Profitability metrics show a return on equity of 0.848 and a return on assets of -1.28, both of which are below the typical thresholds for a profitable pharmaceutical company. The company's operating income is negative at £-7.09 million, and net income is also negative at £-4.71 million. These figures suggest that OKYO Pharma is not currently generating sufficient revenue to cover its operating costs.

The company's revenue is not disclosed in the available data, but it is likely concentrated in its core therapeutic areas of immuno-oncology and targeted therapies. Given the biotechnology industry's reliance on a few key products or clinical trials, any delay or failure in these areas could significantly impact the company's financial performance.

Looking ahead, OKYO Pharma is expected to continue experiencing financial challenges. The company's operating income and net income are both negative, and there is no indication of a near-term turnaround. The company's capital expenditure is minimal at £-1,210, suggesting limited investment in new facilities or equipment. The company's future growth will depend heavily on the success of its clinical trials and the ability to secure additional funding.

Risk factors for OKYO Pharma include its high dependence on a limited number of clinical programs and the inherent risks associated with drug development, such as regulatory approval delays and clinical trial failures. The company's liquidity risk is rated as low, but its equity position is negative, which could lead to dilution if the company needs to raise additional capital. The company's dilution risk is also rated as low, but this could change if the company needs to issue more shares to fund operations.

Recent events include the publication of analyst estimates, which show a mean price target of £8.33 and a median price target of £7.00. The mean recommendation is 2.00, indicating a "buy" rating, with four "buy" recommendations and no "strong buy" or "hold" ratings. These analyst estimates suggest that the market sees potential in OKYO Pharma's pipeline and business model, despite its current financial challenges.